

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶: A61K 33/36, 31/19, 31/045	A1	(11) International Publication Number: WO 99/18978 (43) International Publication Date: 22 April 1999 (22.04.99)
(21) International Application Number: PCT/US97/18389 (22) International Filing Date: 14 October 1997 (14.10.97) (71)(72) Applicant and Inventor: RICKETTS, David, J. [US/US]; 3672 Provincetown Avenue, Irvine, CA 96626 (US). (74) Agent: KRAWITZ, Willie; 3001 Chapel Hill Road, Orange, CA 92867 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: BOVINE TEAT DIP (57) Abstract An iodophor teat dip is disclosed comprising a solution of a fatty alcohol polyglycol ether carboxylic acid, glycerin, I ₂ , I ⁻ (or HI) and, a pH buffer. The teat dip reduces the spread of mastitis infection, imparts a smoother teat condition, improves milk let down, and has few discernible long term effects.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AI.	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Benin	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

BOVINE TEAT DIP

An iodophor teat dip is disclosed comprising a solution of a fatty alcohol polyglycol ether carboxylic acid, glycerin, I_2 , I^- (or HI) and, a pH buffer. The teat dip reduces the spread of mastitis infection, imparts a smoother teat condition, improves milk let down, and has few discernible long term effects.

This invention relates to a new and improved iodophor teat dip containing I_2 and I^- (or HI), a specific surfactant, and glycerin which is suitable for reducing the spread of mastitis infection, and improving teat appearance and skin condition; this in turn enables faster let down and milk out.

Many types of teat dip similar formulations have been employed in the past, and typical examples are found in U.S. Patents 2,977,315; 3,950,554; 4,049,830 4,258,056; 4,371,517; 4,671,958; 4,678,668; 4,940,702; 5,028,427; 5,175,160; 5,208,257; and, German Patent 2,936,934.

20

The use of I_2 with I^- (or HI) which complexes, rather than reacts with the surfactant to produce unwanted and possibly toxic reaction products, is disclosed in U.S. Patents 2,599,140; 2,710,277 and 2,977,315 which describe tamed iodine or iodophor, etc. Also, the use of polyethenoxy detergents and I_2 is disclosed in an article by Benjamin Carroll, in the Journal of Bacteriology, 69; 413-417, (1955).

30

2

In an attempt to avoid the use of I_2 and I_- (or HI), the use of bromo-nitro-propanol as the germicide in teat dips is disclosed in U.S. Patent 4,049,830, but this latter formulation is considered to have insufficient germicidal properties compared to using iodine.

Consequently, present commercial teat dip formulations have been developed to combine desired germicidal properties with suitable emolliency, and include surfactants such as 9 - 12 mole ethoxylated phenols containing I_2 , I- and glycerine.

A surfactant of this type used in a teat dip is sold by Norman Fox & Co. under the trade name of NORFOX N-P9, and listed in "McCutcheon's Emulsifiers and Detergents", 1989 specifically for use with iodophors.

However, the NORFOX N-P9 formulation tends to cause the teat skin to become chapped, cracked and calloused, which in turn leads to infection, which can provide a mastitis site, and weaken the cow for other infections, delayed milk let down, and bovine discomfort when milking.

Another type of teat dip is sold as Klenzade™ Teat Guard, containing a nonyl phenoxy polyethoxy ethanol surfactant having 1% titratable iodine, but this product does not keep a soft teat skin.

3

Still other bovine teat dip formulations have employed an emollient such as lanolin, but these formulations have failed to exhibit the desired characteristics of emolliency.

5 A bovine teat dip formulation is desired which has a suitable capability for dispersing I₂ and I⁻ (or HI); does not form toxic or objectionable compounds with I₂; improves the teat appearance; reduces teat callousing and cracking; improves milk let down; reduces discomfort when milking; maintains a suitable
10 capability for reducing the spread of mastitis; has a reasonably good phase stable shelf life over a reasonably wide temperature range; and, is inexpensive to formulate.

THE INVENTION:

15 According to the invention, an iodophor teat dip formulation is provided comprising an emulsifier/dispersant of water soluble, nonionic, fatty alcohol polyglycol ether carboxylic acids; glycerin, and the like; effective amounts of I₂ and I⁻ (or HI, and the like); and a pH buffer. A suitable emulsifier/dispersant of
20 this type is sold by Alcolac Inc. under the trade names of AKYPO™RLM-45, AKYPO™RLM-100, AKYPO™RLM-130 and AKYPO™RLM-160, and mixtures thereof, the preferred composition being AKYPO™RLM-100 (Chemical Abstracts Registry 74349-89-6).

As described in "McCutcheon's Emulsifiers & Detergents",
25 1989, these AKYPO™RLM emulsifiers/dispersants are listed for personal care products to improve skin feel, in high electrolyte household and industrial formulae, and as an emulsifier for synthetic latex, but they are not listed for use in teat dip formulations. The entire contents of "McCutcheon's Emulsifiers
30 & Detergents" 1989 - 1994 are incorporated herein by reference.

However, according to the invention, it has been discovered unexpectedly that used in conjunction with appropriate amounts of glycerin, an iodophor such as I_2 , I^- (or HI) and, a pH buffer, these water soluble, emulsifiers/dispersants produce a teat dip
5 having the above requisite properties. An adequate, liquid phase stable life over a wide range of ambient temperatures is obtained and moreover, the emulsifier/dispersant probably complexes the iodine and maintains the iodine in solution; this prevents the iodine from precipitating and forming a separate, solid phase.

10

Also, the emulsifier/dispersants function together with the glycerine to impart the necessary emolliency for smooth teats, with reduced cracking, callousing and sores. This lessens the risk of infection sites leading to mastitis, and other diseases.

15

The AKYPO[™]RLM emulsifiers/dispersants used in the formulation are laureth/myristic (11 - 17) carboxylic acids, with an HLB (Hydrophilic/Lipophilic Balance) number of about 10 - 16; AKYPO[™]RLM-100 itself has an HLB of 14.8. The formulation may
20 have a small content (e.g., 5%) of stearic acid.

Typical formulations comprise I_2 : about 0.45% - 1.3%; HI , or equivalent (e.g., KI , NaI , CaI_2 , etc., and mixtures thereof): sufficient to form about 0.25% - 0.3% I^- ; glycerin, and the like:
25 about 5% - 12.5%; a buffer such as citric acid and/or lactic acid; and, caustic for adjusting the pH to about 4.0 - 5.5, and preferably to about 4.8 - 5.2; emulsifier/dispersant: about 7.5% - 12.5%; and, water: balance, all parts by weight.

30

5

If the glycerin content is below about 5%, the formulation did not appear effective. Other hydroxy equivalents to the preferred glycerine may be used, and include: sorbitol; mannitol; galacticol; 1,2,6-hexanetriol; non-ionic polyethylene glycol
5 having a molecular weight of from 100 to 800; the propylene and di-propylene glycols; the pentitols such as arabitol; and, mixtures thereof.

If the emulsifier/dispersant content is below about 7.5%,
10 the formulation becomes unstable due to lack of iodine complexing capability, and if the emulsifier/dispersant content is above about 12.5%, no significant improvement was observed.

Using an AKYPO[®]RLM-100 emulsifier/dispersant of about 10%;
15 an I₂ content of about 1.05%; an I⁻ content of about 0.28%; about 10% glycerin; citric acid to buffer the pH; caustic to obtain a pH range of about 4.8 - 5.2; and the balance water (all parts by weight), a suitable formulation was produced having a phase-stable shelf life of about two (2) years within an ambient
20 temperature range of about 30°F - 110°F. For a bovine teat dip, the formulation may be produced as a concentrate and then diluted with water prior to use.

25

30

6

EXAMPLE 1. Using the above formulation, several herds totalling 2,600 dairy cows was treated during a four month period with about 625,000 teat dips. The herd initially had a low mastitis and infection rate, and use of the above formulation neither
5 improved or worsened the condition of the herd. However, there was a significant improvement in teat appearance, such as a smoother teat, with significantly fewer cracks and a consequent lessened opportunity for spreading an infectious disease such as mastitis. Also there was noted a greater improvement in faster
10 let down and onset of milking, indicating reduced irritation of the cow teats. The life span of cows is about three to seven years, and during the period commencing from the four month tests in 1988 to 1994, no significant change in the herd life span was noted.

15

EXAMPLE 2. In a 1994 test, 12 dairy herds of about 200 cows each were treated with the above formulation, and a noticeable improvement in teat condition was observed within about ten (10) days. Fewer cracks, sores, callousing, etc., appeared, resulting
20 in the cow teats being much easier to prepare for milking and a consequent faster milking operation due to less discomfort.

Also, there was no increase in the somatic (white cell) count, an increase in this cell count being the first sign of a
25 reduced resistance to infectious disease such as mastitis. Additionally, there was a decreased reaction of milker's hands such as chapping, etc., compared to using the NORFOX NP-9 nonyl phenoxy surfactant.

In a fourth test, a male subject in his mid-fifties washed the back of one hand with the concentrate of this invention, the other hand being used as a control. The daily treatment was designed to remove burn scar tissue, and after 2 months of washing, a slow but noticeable improvement was observed.

The concentrate was formed with a foamer-thickener to produce a 0.75% I₂ skin wash.

10 Additionally, the formulation of this invention may be augmented other less expensive teat dips to reduce costs. In this type of usage, about 0.045% by weight of the concentrate is used, the balance being the less expensive teat dip.

15 The concentrate also may be employed to protect the hands when working with food, and when working with food and medical utensils. Also, the diluted concentrate is useful to protect the hands during contact with sanitizing iodine solutions used for example in conjunction with pet shampoos.

20

This concentrate may then be diluted to produce various skin and body care products for use in a carrier such as commercial liquid soaps, sprays, powders, creams, ointments and mixtures thereof to improve skin smoothness, to reduce chapped, scratched
5 or abraded hands, or rashes; as a surgical scrub; as a skin germicide for cuts, dressings, wounds, etc; for acne treatment; for animal and pet shampoos, etc.

For these uses, the formulation of this invention may
10 include germicides, insect repellents, perfumes, moisturizers, antifungal agents, emollients, humectants, defoamers, antibiotics, additional specific soaps, etc.

In the diluted form, such as in liquid soap, ointment, etc.,
15 a typical amount of concentrate at the lower concentration level is about 30 ppm, and at the higher concentration level, the I₂ concentration should not exceed about 1.1% by weight. The I⁻ may be formulated as an ion of Na, K, Mg, Fe, Zn, Mn, Ca, H⁺, etc..

20 While acne itself is not considered a serious disease, it does pose psychological problems, and hence any alleviation of acne and/or associated skin scarring effects would be desirable. The above formulation of this invention was tested daily for various periods of time on three subjects, ranging in age from 14
25 years (female) - test period 1.5 months (applied with a liquid skin care soap); 28 years (male) - test period 1 month (applied as a dilute solution); and, 42 years (female) - test period 9 months (applied with a liquid skin care soap). All three tests resulted in complete acne remission, with mitigation of scarring
30 due to skin peeling.

9

The teat dip and method of this invention provides a product having good germicidal properties, and which imparts a smoother teat with fewer callouses, roughness, sores and cracking. Use of the formulation thus reduces entry sites for infection and subsequent spreading of disease such as mastitis, and milking is made easier due to less teat irritation.

Moreover, the teat dip formulation of this invention is relatively inexpensive and has a reasonably good shelf life at ambient conditions.

It has also been found that once the cow teats have been improved to the point where they are in a healthy condition, the teat concentrate may be used at a greater dilution to reduce costs and still maintain their healthy status.

The laureth/myristic surfactant employed in the formulation of this invention may be used in conjunction with I₁ and I₂ as a concentrate, generally containing: I₁: 2% - 16%; I₂: 3% - 40%; laureth/myristic surfactant: 50% - 95%; and, water: balance, all parts by weight. A preferred concentrate contains: I₁: 6.8%; I₂: 22%; RLM™100: 66%; and, water: 5.2%, all parts by weight.

25

30

CLAIMS:

CLAIM 1. A teat dip solution, comprising: a water soluble solution of a non-ionic, laureth (11 - 16) carboxylic acid having an HLB of about 10 - 16; about 7.5% - 12.5%; an effective amount
5 of an iodophor; glycerin, and the like: about 5% - 12.5%; a buffer; an agent for adjusting the solution pH to about 4.0 - 5.5; and, water: balance, all parts by weight.

CLAIM 2. A concentrate solution suitable, by dilution, for skin
10 care and germicide use, comprising: a water soluble solution of a non-ionic, laureth/myristic (11 - 16) carboxylic acid having an HLB of about 10 - 16; about 50% - 95%; I⁻: about 2% - 16%; I₂: 3% - 40%; and, water: balance, all parts by weight.

CLAIM 3. The solution of Claim 2, admixed with a carrier, the
15 concentrate solution comprising from about 30 ppm concentration in the carrier to about 1.1% I₂ concentration in the carrier.

CLAIM 4. The solution of Claim 3, comprising: I⁻: about 6.8%;
20 I₂: about 22%; laureth/myristic (11 - 16) carboxylic acid: about 66%; and, water: about 5.2%, all parts by weight.

CLAIM 5. The solution of Claim 3, in which the carrier is
25 selected from the class consisting of liquid soaps, sprays, powders, creams, ointments and mixtures thereof.

CLAIM 6. The solution of Claim 3, in which the carrier includes
a foamer-thickener.

CLAIM 7. A method for treating acne and scar tissue, comprising applying the solution of Claim 2 to the acne and scar tissue.

CLAIM 8. The solution of Claim 1, comprising: a water soluble
5 solution of a laureth/myristic (11 - 16) carboxylic acid having an HLB of about 10 - 16: about 7.5% - 12.5%; an I₂ content of about 0.45% - 1.3%; HI, or equivalent: sufficient to form about 0.25% - 0.3% I⁻; glycerin, and the like: about 5% - 12.5%;
a buffer; caustic for adjusting the solution pH to about
10 4.0 - 5.5; and, water: balance, all parts by weight.

CLAIM 9. The solution of Claim 8, in which the laureth/myristic (11 - 16) carboxylic acid has an HLB of about 14.8 .

15 CLAIM 10. The solution of Claim 2, in which about 0.045% by weight of the concentrate is employed to augment a teat dip.

CLAIM 11. The solution of Claim 8, which contains glycerine, sorbitol, mannitol, galacticol, the propylene and di-propylene
20 glycols, 1,2,6-hexanetriol, pentitols including arabitol, non-ionic polyethylene glycol having a molecular weight of from 100 - 800, and mixtures thereof.

CLAIM 12. The solution of Claim 8, having a phase stable shelf
25 life of about two years at ambient temperature.

12

CLAIM 13. The solution of Claim 8, comprising a non-ionic, laureth/myristic (11 - 16) carboxylic acid: about 10%; an I₂ content of about 0.25% - 0.3%; about 10% glycerin; a pH buffer; caustic to obtain a solution pH range of about 4.0 - 5.5; and,
5 the balance water, all parts by weight.

CLAIM 14. The solution of Claim 8, comprising: laureth/myristic (11 - 16) carboxylic acid with an HLB of 14.8; an I- content of about 0.28%; a buffer of citric or lactic acid;
10 and, caustic to adjust the solution pH to about 4.8 - 5.2 .

CLAIM 15. A method of treatment for teats to reduce the spread of infectious disease, by applying to the teat area a solution, comprising: a water soluble solution of a non-ionic,
15 laureth/myristic (11 -16) carboxylic acid having an HLB of about 10 - 16: about 7.5% - 12.5%; an effective amount of an iodophor; glycerine, and the like: about 5% - 12.5%; a buffer; a caustic for adjusting the solution pH to about 4.0 - 5.5; and, water: balance, all parts by weight.

20

CLAIM 16. The method of Claim 15, in which the solution comprises a laureth/myristic (11 - 16) carboxylic acid having an HLB of about 10 - 16: about 7.55 - 12.5%; and I₂ content of about 0.45% - 1.3%; HI or equivalent: sufficient to form about
25 0.25% - 0.3%I-; glycerin, and the like: about 5% - 12.5%; a buffer; caustic for adjusting the solution pH to about 4.0 - 5.5; and, water: balance, all parts by weight.

30

13

CLAIM 17. The method of Claim 15, in which the laureth/myristic (11 - 16) carboxylic acid has an HLB of about 14.8 .

CLAIM 18. The method of Claim 15, in which the buffer is
5 selected from the class consisting of citric acid, lactic acid and mixtures thereof, and the solution pH is about 4.8 - 5.2 .

CLAIM 19. A teat dip solution, comprising: a water soluble solution of a non-ionic, laureth (11 - 16) carboxylic acid having
10 an HLB of about 10 - 16: about 7.5% - 12.5%; an effective amount of stabilized iodine; glycerin, and the like: about 5% - 12.5%; a buffer; an agent for adjusting the pH to about 4.0 - 5.5; and water: balance, all parts by weight.

15 CLAIM 20. The method of treatment according to Claim 10, comprising applying to the teat area a soluble solution of a non-ionic, laureth (11 - 16) carboxylic acid having an HLB of about
10 - 16: about 7.5% - 12.5%; an effective amount of stabilized iodine; glycerine, and the like: about 5% - 12.5%; a buffer; a
20 caustic for adjusting the solution pH to about 4.0 - 5.5; water: balance, all parts by weight.

25

30

INTERNATIONAL SEARCH REPORT

International application N .
PCT/US97/18389

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 33/36, 31/19, 31/045

US CL :424/672, 405; 514/558, 738

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/672, 405; 514/558, 738

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEMICAL ABSTRACTS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,012,504 A (ECKOLS) 15 March 1977, see entire document.	1-20
A	US 5,529,770 A (MCKINZIE et al) 25 June 1996, see entire document.	1-20
X	US 5,534,266 A (RICKETTS) 09 July 1996, see entire document.	1-6 and 8-20
A	US 5,641,498 A (LOOSEMORE) 24 June 1997, see entire document.	1-6 and 8-20
A	US 5,651,977 A (KROSS) 29 July 1997, see entire document.	1-20

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

10 DECEMBER 1997

Date of mailing of the international search report

03 FEB 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JAMES H. REAMER

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet)(July 1992)*